ArticleNature2024
Origins and impact of extrachromosomal DNA.
Abstract read
In one paragraph
Article in Nature, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 122 papers.
0numbers the graph read from it
0cells of the map it votes in
122citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
122 citing papers in PubMed.
- A system-level metastable model of cancer evolution: integrating replication stress, cell cycle deregulation and chromosomal instability.Annals of medicine · 2026Review
- Micronuclear ecDNA constrains tumor cell fitness and is associated with favorable patient survival.Nature genetics · 2026Article
- A Living Multi-Omics PDX Biobank of High-Risk Sarcomas Reveals ecDNA-Driven Oncogene Amplification in Osteosarcoma and Enables Preclinical Precision Oncology.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Protocol for rolling circle amplification-based nanopore sequencing of eccDNA from cell and plasma samples.STAR protocols · 2026Article
- Circulating tumour DNA and extrachromosomal DNA in prostate and bladder cancer: biology, clinical applications and future perspectives.World journal of urology · 2026Review
- Genomic instability, postoperative recurrence and therapeutic vulnerabilities in resectable non‑small cell lung cancer (Review).Oncology reports · 2026Review
- Review
- Article
- Shield strike shatter in DNA topology and nuclease interactions.Nature communications · 2026Article
- Clustered structural variant hotspots enable oncogenic addiction and plasticity in osteosarcoma.bioRxiv : the preprint server for biology · 2026Article
- Extrachromosomal DNA as a platform for epigenetic reprogramming in cancer.Molecular cancer · 2026Review
- The shared evolutionary capacities of plasmids and extrachromosomal DNA.Nature reviews. Genetics · 2026Review
- Quantitative and sensitive neuroblastoma minimal residual disease detection using extrachromosomal DNA (ecDNA) breakpoints.bioRxiv : the preprint server for biology · 2026Article
- Advancing the applications of liquid biopsies in oncology.Nature reviews. Genetics · 2026Review
- Extrachromosomal DNA in urothelial carcinoma: mechanisms and clinical applications.Nature reviews. Urology · 2026Review
- scAmp enables focal gene amplification analysis from single-cell data.Nature communications · 2026Article
- Genome-scale molecular profiling from routine histopathology with a multimodal pathology foundation model.Research square · 2026Article
- Examining the role of extrachromosomal DNA in lung cancer.Journal of the National Cancer Institute · 2026Article
- Hybrid extrachromosomal DNA in HPV-driven cancers.Journal of virology · 2026Review
- Multiomic profiling links L1 retrotransposition to genomic instability and ecDNA in bladder cancer.Nature communications · 2026Article
62 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors.
Chris Bailey *Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
Oriol Pich *Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.ORCID 0000-0002-1956-1882
Kerstin TholCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.ORCID 0000-0002-4624-118X
Thomas B K WatkinsDepartment of Pathology, Stanford University, Stanford, CA, USA.
Jens LuebeckDepartment of Computer Science and Engineering, University of California at San Diego, La Jolla, CA, USA.ORCID 0000-0003-4391-979X
Andrew RowanCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
Georgia StavrouCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.ORCID 0000-0002-8427-5233
Natasha E WeiserDepartment of Pathology, Stanford University, Stanford, CA, USA.ORCID 0000-0001-9971-2961
Bhargavi DameracharlaDepartment of Pathology, Stanford University, Stanford, CA, USA.
Robert BenthamCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Wei-Ting LuCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.ORCID 0000-0002-1405-4806
Jeanette KittelCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
S Y Cindy YangDepartment of Pediatrics, Stanford University, Palo Alto, CA, USA.
Brooke E HowittDepartment of Pathology, Stanford University, Stanford, CA, USA.ORCID 0000-0002-0309-6680
Natasha SharmaCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Maria LitovchenkoCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Roberto SalgadoDepartment of Pathology, ZAS Hospitals, Antwerp, Belgium.ORCID 0000-0002-1110-3801
King L HungCenter for Personal Dynamic Regulomes, Stanford University, Stanford, CA, USA.ORCID 0000-0002-3662-4662
Alex J CornishDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.ORCID 0000-0002-3966-3501
David A MooreCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.ORCID 0000-0002-6296-1312
Richard S HoulstonDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.ORCID 0000-0002-5268-0242
Vineet BafnaDepartment of Computer Science and Engineering, University of California at San Diego, La Jolla, CA, USA.
Howard Y ChangCenter for Personal Dynamic Regulomes, Stanford University, Stanford, CA, USA.ORCID 0000-0002-9459-4393
Serena Nik-ZainalAcademic Department of Medical Genetics, School of Clinical Medicine, University of Cambridge, Cambridge, UK.ORCID 0000-0001-5054-1727
Nnennaya KanuCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.ORCID 0000-0001-7232-1952
Nicholas McGranahanCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Genomics England Consortium
Adrienne M FlanaganResearch Department of Pathology, University College London, UCL Cancer Institute, London, UK.ORCID 0000-0002-2832-1303
Paul S MischelDepartment of Pathology, Stanford University, Stanford, CA, USA. pmischel@stanford.edu.ORCID 0000-0002-4560-2211
Mariam Jamal-HanjaniCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK. m.jamal-hanjani@ucl.ac.uk.
Charles SwantonCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK. charles.swanton@crick.ac.uk.ORCID 0000-0002-4299-3018
Funding
eDyNAmiC - STANFORDOT2CA278688 · NCI · STANFORD UNIVERSITY · PI PAUL S MISCHEL · 2022 to 2026
$7.7MSoftware and algorithms for elucidating the structure, function, and evolution of extrachromosomal DNAU24CA264379 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BAFNA, VINEET, MESIROV, JILL P. · 2021 to 2025
$3.5MIntegrated ligand and target discovery by chemical proteomics for glioblastoma treatment.R01CA238249 · NCI · STANFORD UNIVERSITY · PI CRAVATT, BENJAMIN F, MISCHEL, PAUL S · 2021 to 2025
$3.3MHyperpolarized C-13 MRI Techniques to Monitor Radiation Therapy Response in Prostate Cancer PatientsR01CA238379 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BOK, ROBERT A, VIGNERON, DANIEL B · 2021 to 2025
$3.3MComputational methods for detecting patterns of complex genomic variationR01GM114362 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Vineet Bafna · 2016 to 2026
$3.1MeDyNAmiC - UCSDOT2CA278635 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Vineet Bafna · 2022 to 2026
$1.8MCancer Research UK CGCATF-2021/100012NCI NIH HHS OT2 CA278635NCI NIH HHS OT2 CA278688NCI NIH HHS R01 CA238249NCI NIH HHS R01 CA238379NCI NIH HHS U24 CA264379NIGMS NIH HHS R01 GM114362Wellcome Trust CC2041
Abstract
Extrachromosomal DNA (ecDNA) is a major contributor to treatment resistance and poor outcome for patients with cancer
Indexed as
DNADNA, NeoplasmGene AmplificationMutagenesisNeoplasmsOncogenesDisease ProgressionEnhancer Elements, GeneticFemaleHumansLymphocytesMaleOrgan SpecificityPromoter Regions, GeneticRecombinational DNA RepairRNA, Long NoncodingDNADNA, NeoplasmRNA, Long Noncoding
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.